Literature DB >> 24134323

Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease.

K-H Jung1, J-J Kim, J-S Lee, W Park, T-H Kim, J-B Jun, D H Yoo.   

Abstract

OBJECTIVES: Diagnosis of adult-onset Still's disease (AOSD) is difficult because of a lack of pathognomonic findings and markers. The aim of this study was to investigate the efficacy of interleukin (IL)-18 and free IL-18 in the diagnosis and follow-up of patients with AOSD.
METHOD: Levels of inflammatory cytokines, IL-18, IL-18 binding protein (IL-18BP), and free IL-18 were compared in 80 AOSD patients and 90 controls. The AOSD patients were divided into active and inactive groups according to disease activity, and the inactive patients were subdivided into a remission subgroup and a low disease activity subgroup. We compared erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ferritin, IL-18, and free IL-18 as disease activity markers in the AOSD patients. Serial serum levels of activity markers were measured in 52 of the 80 AOSD patients at 3- to 6-month intervals.
RESULTS: There were significantly higher levels of IL-18 and free IL-18 in the AOSD patients than in the controls. IL-18 and free IL-18 were significantly higher in the active group than the inactive group (p < 0.001 for all). Unlike other activity markers, IL-18 and free IL-18 levels in the low disease activity subgroup were significantly higher than those in the remission subgroup within the inactive group (p = 0.004 and 0.005, respectively). During serial follow-up, ferritin and IL-18 showed a significant decrease in the responder and remission subgroup.
CONCLUSIONS: IL-18 might be an efficient marker for diagnosis and follow-up of AOSD and might also be a useful predictor of remission, especially in clinically inactive patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24134323     DOI: 10.3109/03009742.2013.824023

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  17 in total

Review 1.  Adult-onset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review.

Authors:  Ken Goda; Tsuneaki Kenzaka; Masahiko Hoshijima; Akihiro Yachie; Hozuka Akita
Journal:  Rheumatol Int       Date:  2019-09-20       Impact factor: 2.631

2.  The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

Authors:  Kuo-Tung Tang; Chia-Wei Hsieh; Hsin-Hua Chen; Yi-Ming Chen; Shih-Hsin Chang; Po-Hao Huang; Joung-Liang Lan; Der-Yuan Chen
Journal:  Clin Rheumatol       Date:  2021-09-17       Impact factor: 2.980

Review 3.  Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety.

Authors:  Dongsheng Hong; Zhihai Yang; Shuyin Han; Xingguang Liang; Kuifen Ma; Xingguo Zhang
Journal:  Drug Des Devel Ther       Date:  2014-11-25       Impact factor: 4.162

Review 4.  Interleukin-18 as a diagnostic marker of adult-onset Still's disease in older patients: a case report and review of the literature.

Authors:  Daisuke Usuda; Yoshiki Furumura; Kento Takeshima; Ryusho Sangen; Yasuhiro Kawai; Yuji Kasamaki; Yoshitsugu Iinuma; Tsugiyasu Kanda
Journal:  J Med Case Rep       Date:  2018-07-10

5.  Utility and drawbacks of [18]F-fluorodeoxyglucose positron emission tomography in the evaluation of adult-onset Still's disease.

Authors:  Dae Hyun Yoo
Journal:  Korean J Intern Med       Date:  2017-10-27       Impact factor: 2.884

6.  Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis.

Authors:  Tomohiro Koga; Remi Sumiyoshi; Kaori Furukawa; Shuntaro Sato; Kiyoshi Migita; Toshimasa Shimizu; Masataka Umeda; Yushiro Endo; Shoichi Fukui; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Fumiaki Nonaka; Akihiro Yachie; Hideaki Kondo; Takahiro Maeda; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2020-05-07       Impact factor: 5.156

7.  Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity.

Authors:  Holger Kudela; Susanne Drynda; Anke Lux; Gerd Horneff; Joern Kekow
Journal:  BMC Rheumatol       Date:  2019-02-28

Review 8.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

Review 9.  Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.

Authors:  Meng-Yan Wang; Jin-Chao Jia; Cheng-De Yang; Qiong-Yi Hu
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

Review 10.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.